Regulation - Research, Merck & Co


Current filters:

ResearchMerck & Co

Popular Filters

Merck and Endocyte pull CMA for vintafolide and companion imaging component in EU


US pharma giant Merck & Co and Endocyte have withdrawn their conditional marketing authorization applications…

EndocyteEuropeMerck & CoOncologyPharmaceuticalRegulationResearchvintafolide

Merck & Co updates on near-term opportunities and strategy

Merck & Co updates on near-term opportunities and strategy


US pharma giant Merck & Co, which has just sold its consumer health care business to Bayer for $14.2…

Merck & CoPharmaceuticalRegulationResearch

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year


Merck & Co yesterday provided an overview of the clinical trial program for V503, the company’s investigational…

Merck & CoNorth AmericaPharmaceuticalRegulationResearchV503Vaccines

American Diabetes Association calls for independent review of incretin-based therapy


The American Diabetes Association is asking all pharmaceutical companies involved in the development…

DiabetesJanuviaMerck & CoPharmaceuticalRegulationResearch

Merck & Co gets all clear to continue Vytorin study; FDA warns on Pfizer's Zithromax


US pharma giant Merck & Co said yesterday that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT…

Antibiotics and Infectious diseasesCardio-vascularMerck & CoNorth AmericaPfizerPharmaceuticalRegulationResearchVytorinZithromax

Merck & Co to drop Tredaptive development in USA


US drug giant Merck & Co (NYSE: MRK) said yesterday that, following disappointing clinical trial results…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationResearchTredaptive

Merck & Co to file for approval of two heart drugs next year


US drugs giant Merck & Co (NYSE: MRK) says that, following a review of the clinical trial data and discussions…

anacetrapibCardio-vascularEuropeMerck & CoNorth AmericaPharmaceuticalRegulationResearchTredaptivevorapaxar

Merck & Co closes odanacatib trial early on good results in osteoporosis


US drug giant Merck & Co (NYSE: MRK) says it is halting a Phase III trial of its investigational osteoporosis…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalRegulationResearch

GlaxoSmithKline readies for filing of diabetes drug albiglutide on positive final data


UK pharma giant GlaxoSmithKline (LSE: GSK) says that positive data from the Phase III Harmony 8 study…

albiglutideDiabetesGlaxoSmithKlineJanuviaMerck & CoPharmaceuticalRegulationResearch

Victoza US label update includes superior efficacy over Januvia, says Novo Nordisk


The US Food and Drug Administration has approved an update to the product label for Victoza (liraglutide…

DiabetesJanuviaLevemirMerck & CoNorth AmericaNovo NordiskPharmaceuticalRegulationResearchVictoza

FDA calls for more data on Merck combo drug; Good results with allergy drug


The US Food and Drug Administration (FDA) has issued a Complete Response Letter to drug giant Merck &…

ALK AbelloatorvastatinCardio-vascularezetimibeImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulationResearch

Merck & Co confirms NDA filing for suvorexant in 2012


US drugs giant Merck & Co (NYSE: MRK) yesterday provided an update on the development program for suvorexant,…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationResearchsuvorexant

Merck & Co drops combo diabetes drug Janacti filing in Europe; presents data on discontinued vorapaxar study


The European Medicines Agency says it has been formally notified by Merck Sharp & Dohme (Europe), a subsidiary…

Cardio-vascularDiabetesJanactiMerck & CoPharmaceuticalPioglitazoneRegulationResearchsitagliptinvorapaxar

Merck & Co debuts Nexplanon in USA; gets negative FDA response on Zoely and Saflutan


Merck & Co (NYSE; MRK), the USA’s second largest drugmaker, says that its Nexplanon (etonogestrel…

DiabetesJanuviaMarkets & MarketingMerck & CoNexplanonOphthalmicsPharmaceuticalRegulationReproductiveResearchSaflutanZoely

Company Spotlight



Back to top